Glycine

Orphan designation: Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate-aminotransferase gene Treatment of primary hyperoxaluria type 1, 21/03/2012 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, System, Primary, Calcium oxalate, Enzyme, DSM-IV codes, Cell, Disease, Abdominal pain, Patient, Committee, Knowledge, Kidney failure, Organic acid, Regulation, EMA, IRIS, Glycine, Protein, Human, AGXT, Urine, European, COMP, Urinary tract infection, European Commission, Kidney, Safety, Blood, Marketing, Liver, Medicine, Pharmaceutical industry

Orphan designation: Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate-aminotransferase gene Treatment of primary hyperoxaluria type 1, 21/03/2012 Withdrawn

Key Points: 


Orphan designation: Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate-aminotransferase gene Treatment of primary hyperoxaluria type 1, 21/03/2012 Withdrawn

Celluma Light Therapy Introduces the RESTORE Hair Therapy System

Retrieved on: 
Thursday, March 14, 2024
DHT, Vitamin, Adenosine triphosphate, Serum, Inflammation, Zinc, Hair loss, Glycine, Scalp, ATP, FDA, Microcirculation, Peptide, Cosmetics

TUSTIN, Calif., March 14, 2024 /PRNewswire/ -- BioPhotas, Inc., the makers of Celluma Light Therapy and market leader in therapeutic LED light therapy devices, announced today the launch of the RESTORE Hair Serum, an optimized scalp and hair formulation that complements the award-winning Celluma RESTORE LED device to provide a complete hair-restoration solution.

Key Points: 
  • TUSTIN, Calif., March 14, 2024 /PRNewswire/ -- BioPhotas, Inc., the makers of Celluma Light Therapy and market leader in therapeutic LED light therapy devices, announced today the launch of the RESTORE Hair Serum, an optimized scalp and hair formulation that complements the award-winning Celluma RESTORE LED device to provide a complete hair-restoration solution.
  • "It's an amazingly elegant formulation that is clear and easily absorbed into the scalp so that it can be used daily to maximize the Celluma Light Therapy results."
  • For the growing number of professionals and individuals achieving significant and visible results with the FDA-cleared Celluma RESTORE Light Therapy device for hair restoration, this serum is an ideal complement for use between each light therapy treatment.
  • According to Mr. Cluff, "the Celluma RESTORE light therapy device has been available since receiving FDA-clearance for hair restoration in 2021.

Draslovka and Barrick Gold Commence Commercial Use of Glycine Leaching Technology for Gold Mining

Retrieved on: 
Thursday, February 29, 2024
Environment, Technology, Chemicals, Plastics, Manufacturing, Sustainability, Mining, Minerals, Machine Tools, Metalworking & Metallurgy, Artificial Intelligence, Natural Resources, Barrick Gold, Glycine, Bulyanhulu Gold Mine, WAD, Gold, Pleasure, Partnership

Draslovka a.s ("Draslovka"), a provider of sustainability-led technologies, reagents and services for mining and the energy transition, has progressed its previously announced partnership with Barrick Gold Corporation ("Barrick") and today announces the start of commercial use of its revolutionary glycine leaching technology for gold, GlyCat™ (“GlyCat”), at Barrick’s Buylanhulu operation in Tanzania.

Key Points: 
  • Draslovka a.s ("Draslovka"), a provider of sustainability-led technologies, reagents and services for mining and the energy transition, has progressed its previously announced partnership with Barrick Gold Corporation ("Barrick") and today announces the start of commercial use of its revolutionary glycine leaching technology for gold, GlyCat™ (“GlyCat”), at Barrick’s Buylanhulu operation in Tanzania.
  • In addition, Draslovka and Barrick’s strategic partnership will now include a broader testing programme in 2024 that will span multiple mining sites.
  • At Bulyanhulu Gold Mine, the GlyCat pilot programme has led to an 80% reduction in cyanide consumption while achieving gold recoveries that are comparable to traditional cyanidation.
  • Pavel Bruzek Jr, CEO of Draslovka, commented: “This licensing agreement follows a highly successful pilot programme that proved the major benefits GlyCat offers to the gold mining industry.

Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
FDA, Research, IRON, Glycine, Erythropoiesis, Food, EPP, PV, Sodium- and chloride-dependent glycine transporter 1, G&A, AURORA, Iron, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ruxolitinib, Light, Porphyria, Inflammation, Poster, Sunlight, Society, ASH, Development, Photosensitivity, Hematology, Quality of life, Phase 10, Anemia, PPIX, Safety, MF, XLP, Pain, Patient, Administration, Polycythemia, Rare-earth element, Pharmaceutical industry, Vaccine, Disc

Third Quarter 2023 Financial Results:

Key Points: 
  • Third Quarter 2023 Financial Results:
    Cash Position: Cash and cash equivalents were $370.5 million as of September 30, 2023, which are expected to fund our operational plans well into 2026.
  • Research and Development Expenses: R&D expenses were $14.4 million for the quarter ended September 30, 2023, as compared to $7.9 million for the quarter ended September 30, 2022.
  • General and Administrative Expenses: G&A expenses were $4.5 million for the quarter ended September 30, 2023, as compared to $2.6 million for the same period in 2022.
  • Net Loss: Net loss was $14.1 million for the quarter ended September 30, 2023, as compared to $16.2 million for the third quarter of 2022.

Solgar® Cellular Nutrition Emerges to Take Longevity Cell Deep

Retrieved on: 
Tuesday, October 24, 2023
Nicotinamide adenine dinucleotide, Nicotinamide riboside, Science, Ageing, Scientific Reports, NAD, Food, Biomarker, Food and Drug Administration, Research, Cell, UA, RCT, Exercise, Development, Dietary supplement, Leg, JAMA Network Open, The Bountiful Company, Disease, Clinical trial, Urolithin A, Hand, Cysteine, Nutrient, Randomized controlled trial, NR, Oxidative stress, Longevity, Mobile phone, Glycine

HOBOKEN, N.J., Oct. 24, 2023 /PRNewswire/ -- Solgar®, a Nestlé Health Science brand and a leader in scientifically-backed vitamin and nutritional supplements for more than 70 years, today unveiled its Solgar® Cellular Nutrition line of dietary supplements developed to help fight cellular decline and promote cell health. Solgar Cellular Nutrition's products – Energy, Strength & Renewal, and Protect – target cellular decline through clinically studied ingredients, including Nicotinamide Riboside (NR), Urolithin A (UA) as well as Glycine & N-Acetyl Cysteine (GlyNAC). These products are available online through Solgar Cellular Nutrition at www.solgar.com/cellular-nutrition.  

Key Points: 
  • These products are available online through Solgar Cellular Nutrition at www.solgar.com/cellular-nutrition .
  • "These scientific advances along with new cellular nutrition research led us to develop our new line of Solgar Cellular Nutrition products.
  • These products – Energy, Strength & Renewal, and Protect – feature nutrients that work with the body's natural processes deep inside cells to help fight sources of cellular decline and promote overall cell health.
  • To learn more about Solgar Cellular Nutrition and purchase its cellular health products, please visit www.solgar.com/cellular-nutrition .

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

Retrieved on: 
Monday, October 23, 2023
Colon, Oncolytics Biotech, Genetics, News, Lung, Disease, Risk, Messenger, Lijun International Pharmaceutical (Holding) Co. Ltd., BNTX, Glycine, BioNTech, G12, Hope, RET, Prostate cancer, BRCA2, Cancer, Immune system, Pancreatic cancer, ORR, Hand, University, Roche, Therapy, Patient, Natural history of disease, DNA, CR, Eli Lilly and Company, CAD, 23andMe, JD, OTC, Eli Lilly, FOLFIRINOX, BRCA, Research, Clinical trial, BBB National Programs, Survival rate, Aspartic acid, Valine, Woman, ONC, MD Anderson Cancer Center, TSX, PCCP, Survival, FDA, Lilly, Attention, AACR, Incidence, BRCA1, New View (Eleanor Friedberger album), MBA, KRAS, Entrepreneurship, Breast, Diagnosis, Prostate, FTD, Pharmaceutical industry, Medical imaging, Vaccine, Nature

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- USA News Group - Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully understood, pancreatic cancer's 5-year survival rate is currently only 12%. New analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder. Thankfully, within the biotech sector, there have been plenty of developments giving hope in the fight against pancreatic cancer, including those from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Eli Lilly and Company, Roche Holding AG (OTC:RHHBY), BioNTech SE (NASDAQ:BNTX), and even 23andMe Holding Co (NASDAQ:ME).

Key Points: 
  • As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder .
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • The BRCA1 and BRCA2 variants may also be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers.
  • "It's an important milestone that shows we're headed in the right direction – and this means so much to all those affected by pancreatic cancer."

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

Retrieved on: 
Monday, October 23, 2023
Colon, Oncolytics Biotech, Genetics, News, Lung, Disease, Risk, Messenger, Lijun International Pharmaceutical (Holding) Co. Ltd., BNTX, Glycine, BioNTech, G12, Hope, RET, Prostate cancer, BRCA2, Cancer, Immune system, Pancreatic cancer, ORR, Hand, University, Roche, Therapy, Patient, Natural history of disease, DNA, CR, Eli Lilly and Company, CAD, 23andMe, JD, OTC, Eli Lilly, FOLFIRINOX, BRCA, Research, Clinical trial, BBB National Programs, Survival rate, Aspartic acid, Valine, Woman, ONC, MD Anderson Cancer Center, TSX, PCCP, Survival, FDA, Lilly, Attention, AACR, Incidence, BRCA1, New View (Eleanor Friedberger album), MBA, KRAS, Entrepreneurship, Breast, Diagnosis, Prostate, FTD, Pharmaceutical industry, Medical imaging, Vaccine, Nature

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- USA News Group - Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully understood, pancreatic cancer's 5-year survival rate is currently only 12%. New analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder. Thankfully, within the biotech sector, there have been plenty of developments giving hope in the fight against pancreatic cancer, including those from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Eli Lilly and Company, Roche Holding AG (OTC:RHHBY), BioNTech SE (NASDAQ:BNTX), and even 23andMe Holding Co (NASDAQ:ME).

Key Points: 
  • As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder .
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • The BRCA1 and BRCA2 variants may also be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers.
  • "It's an important milestone that shows we're headed in the right direction – and this means so much to all those affected by pancreatic cancer."

Leach Testing Underway with GlyCat™ Process

Retrieved on: 
Monday, October 23, 2023
Gold, Glycine, CPG, GPO, CSE, National instrument, Sample, Sodium cyanide, Extractive metallurgy

VANCOUVER, B.C, Oct. 23, 2023 /PRNewswire/ -- Gold Port Corporation (CSE: GPO) (OTCQB: GPOTF) (the "Company") is pleased to announce that leach test work is underway using a new and innovative leaching process.

Key Points: 
  • VANCOUVER, B.C, Oct. 23, 2023 /PRNewswire/ -- Gold Port Corporation (CSE: GPO) (OTCQB: GPOTF) (the "Company") is pleased to announce that leach test work is underway using a new and innovative leaching process.
  • 'Samples from the Groete Gold Project have been received in Australia and are currently under evaluation.
  • Company President and CEO, Adrian F. C. Hobkirk is quoted, "We are excited to be testing state of the art chemical solutions for the extraction of gold from the Groete Gold Deposit.
  • The Company is committed to identifying the most cost effective, environmentally friendly and sustainable recovery process for this significant gold deposit."

Leach Testing Underway with GlyCat™ Process

Retrieved on: 
Monday, October 23, 2023
Gold, Glycine, CPG, GPO, CSE, National instrument, Sample, Sodium cyanide, Extractive metallurgy

VANCOUVER, B.C, Oct. 23, 2023 /PRNewswire/ -- Gold Port Corporation (CSE: GPO) (OTCQB: GPOTF) (the "Company") is pleased to announce that leach test work is underway using a new and innovative leaching process.

Key Points: 
  • VANCOUVER, B.C, Oct. 23, 2023 /PRNewswire/ -- Gold Port Corporation (CSE: GPO) (OTCQB: GPOTF) (the "Company") is pleased to announce that leach test work is underway using a new and innovative leaching process.
  • 'Samples from the Groete Gold Project have been received in Australia and are currently under evaluation.
  • Company President and CEO, Adrian F. C. Hobkirk is quoted, "We are excited to be testing state of the art chemical solutions for the extraction of gold from the Groete Gold Deposit.
  • The Company is committed to identifying the most cost effective, environmentally friendly and sustainable recovery process for this significant gold deposit."

PANCREATIC CANCER ACTION NETWORK ANNOUNCES RECORD-BREAKING ANNUAL RESEARCH INVESTMENT, INCLUDING NEW GRANT AWARDS, WHICH WILL ACCELERATE PROGRESS AGAINST PANCREATIC CANCER

Retrieved on: 
Wednesday, August 30, 2023
Pancreatic cancer, KRAS, Risk, Pancreatic Cancer Action Network, Biotechnology, Policy, Survival, Therapy, MBA, Research, Mentorship, Biomarker, Doctor of Philosophy, A1C, Protein, Glycine, Patient, JD, Immune system, Vutrisiran, Biology, Neoplasm, Memory, Pancreatic tumor, Disease, Peripheral nervous system, Pharmaceutical industry, Management, Medical imaging

LOS ANGELES, Aug. 30, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, today announced its largest ever single-year research investment—more than $34 million—which includes its large-scale scientific and clinical initiatives and nine new grants.

Key Points: 
  • These funds support PanCAN's priority of finding an early detection strategy and accelerating treatment options for people with pancreatic cancer.
  • "This year marks 20 years of PanCAN awarding research grants – and over that time we have established ourselves as the catalyst for change in the pancreatic cancer community.
  • Since 2003, PanCAN has awarded 236 grants to scientists at 78 institutions around the country, building a comprehensive pancreatic cancer research community.
  • In 1999, when the Pancreatic Cancer Action Network (PanCAN) was founded, there were only a handful of scientists focused on pancreatic cancer, and research funding opportunities were scarce.